RenalGuard Solutions, a Milford, MA-based medical device company focused on innovative technologies for the cardiac and vascular markets, completion a $7m financing.
The round was led by Abiomed with participation from existing investors.
RenalGuard Solutions has just launched Reprieve Cardiovascular, a medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF).
Led by Jim Dillon, CEO, Reprieve Cardiovascular is advancing a Guided Diuretic Therapy as a treatment for patients who are fluid-overloaded due to heart failure, with the potential to speed decongestion while protecting core organ function, shorten hospital stays, and reduce re-hospitalization in ADHF patients.
The therapy has the potential to enable precise and predictable management of a patient’s fluid levels, guarding against dangerous fluid imbalances and enabling better control over diuretic therapy thus increasing the diuretic efficiency a patient experiences. Potential benefits include speeding decongestion while protecting core organ function, lessening of symptoms of CHF, such as shortness of breath, ascites, and swelling, reduced time in hospital, reduced readmission rates, and a better quality of life for the patient.
Reprieve utilizes the RenalGuard platform, marketed by RenalGuard Solutions™, Inc.